Cancer drugs among US goods spared from tariffs as China issues first exemptions in trade war
In its first move to spare certain US imports from the trade war, China has offered some relief to cancer drugmakers.
Twelve drugs — mostly chemotherapy agents — featured on the list of products to be exempted from retaliatory tariffs until September 2020. They also belong to the subgroup where tariffs already collected will be returned.
AstraZeneca’s EGFR inhibitor Iressa appears to be the only non-chemo drug in the group. Here’s the list, translated from the Ministry of Finance’s original announcement:
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.